

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Substitute for form 1449/PTO)				ATTY. DOCKET NO. 066742-0040		SERIAL NO. 10/524,952	
				APPLICANT Yeaman, Michael R., et al.			
				FILING DATE February 18, 2005		GROUP 1654	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ₂ (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US	5,420,109	05-30-1995	MARK J. SUTO		
		US	5,789,542	08-04-1998	MARK L. MCLAUGHLIN		
		US	5,752,515	05-19-1998	FERENC A. JOLESZ		
		US	5,268,154	12-07-1993	MARIO PEPI		
		US	5,506,206	04-09-1996	JOHN W. KOZARICH		
		US	5,686,416	11-11-1997	JOHN W. KOZARICH		
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Code ₃ -Number 4-Kind Codes (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No
		WO 99/42119**		08/26/99	PCT		
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		Achilles, K., "Coumarin Derivatives as Protease-Sensitive Prodrugs," <u>Arch. Pharm. Pharm. Med. Chem.</u> 334:209-215 (2001). **					
		Alvarez-Bravo et al., "Novel synthetic antimicrobial peptides effective against methicillin-resistant Staphylococcus aureus," <u>Biochem. J.</u> 302:535-538 (1994) **					
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will be provided under separate cover.

		Annual Reports in Medicinal Chemistry. Eds. Blondelle and Houghten. San Diego: Academic Press, 159-168. **	
		Bessalle, R. "All-D-magainin: chirality, antimicrobial activity and proteolytic resistance" <u>FEBS Lett.</u> 274:151-155 (1990). **	
		Blondelle SE, Houghten RA, "Design of model amphipathic peptides having potent antimicrobial activities," <u>Biochem.</u> 31: 12688-12694 (1992). **	
		Bodanzsky, M. <u>Principles of Peptide Synthesis</u> 1st ed., and 2nd rev. ed. New York: Springer-Verlag, 1984 & 1994, Ch. 7. **	
		Brem, H., et al., "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas" <u>J. Neurosurg</u> 74: 441-446 (1991). **	
		<u>Burger's Medicinal Chemistry and Drug Discovery</u> vol. 1. Ed. M.E. Wolff. John Wiley & Sons, 1995, 619-620. **	
		<u>Combinatorial Chemistry</u> . Eds. Wilson and Czarnick. New York: John Wiley & Sons, 235, 1997. **	
		Davioud-Charvet et al., "A Prodrug Form of a Plasmodium falciparum Glutathione Reductase Inhibitor Conjugated with a 4-Anilinoquinoline," <u>J. Med. Chem.</u> 44:4268-4276 (2001). **	
		Dhawan et al., "In Vitro Resistance to Thrombin-Induced Platelet Microbicidal Protein Is Associated with Enhanced Progression and Hematogenous Dissemination in Experimental Staphylococcus aureus Infective Endocarditis," <u>Infect and Immun</u> 66:3476-3479 (1998). **	
		Expand, <u>The Amphipathic Helix</u> Boca Raton: CRC Press, 1993. **	
		Fields et al., "A Salmonella Locus That Controls Resistance to Microbicidal Proteins from Phagocytic Cells," <u>Science</u> 243:1059-1062 (1989). **	
		Friedrichsen et al., "Application of Enzymatically Stable Dipeptides for Enhancement of Intestinal Permeability. Synthesis and In Vitro Evaluation of Dipeptide-Coupled Compounds," <u>Bioorg Med Chem.</u> 9:2625-2632 (2001). **	
		Garsky et al., "The Synthesis of a Prodrug of Doxorubicin Designed to Provide Reduced Systemic Toxicity and Greater Target Efficacy," <u>J. Med. Chem.</u> 44:4216-4224 (2001). **	
		Goodman and Ro, "Peptidometrics for Drug Design," <u>Burger's Medicinal Chemistry and Drug Discovery</u> vol. 1. Ed. M.E. Wolff. John Wiley & Sons, 1995, 803-861. **	
		Han and Amidon, "Targeted Prodrug Design to Optimize Drug Delivery," <u>AAPS Pharmsci.</u> 2:1-11 (2000). **	
		Javadpour et al., "De novo antimicrobial peptides with low mammalian cell toxicity," <u>J. Med. Chem.</u> 39:3107-3113 (1996). **	
		Kreuter, J., et al. "Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)," <u>Brain Res.</u> 674:171-174 (1995). **	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will be provided under separate cover.

		Lackey et al., "Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase," <u>Biochemical Pharmacology</u> 61:179-189 (2001). **	
		Li et al., "NB2001, a Novel Antibacterial Agent with Broad-Spectrum Activity and Enhanced Potency against β -Lactamase-Producing Strains," <u>Antimicrobial Agents and Chemotherapy</u> 46:1262-1268 (2002). **	
		Li et al., "A Novel Approach to Thymidylate Synthase as a Target for Cancer Chemotherapy," <u>Molecular Pharmacology</u> 59: 446-452 (2001). **	
		Liang et al., "ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs," <u>Journal of Controlled Release</u> 78:67-79 (2002). **	
		Lipka et al, "Transmembrane transport of peptide type compounds: Prospects for oral delivery," <u>Journal of Controlled Release</u> 39:121-129 (1996). **	
		<u>Liposome Technology</u> vols. 1-3, 2nd Edn. Ed. Gregoriadis, G. Boca Raton, FL: CRC Press, 1993. **	
		Lugtenberg and van Alphen, "Molecular architecture and functioning of the outer membrane of Escherichia coli and other gram-negative bacteria," <u>Biochim Biophys Acta</u> . 737:51-115 (1983). **	
		Maloy and Kari, "Structure-Activity Studies on Magainins and Other Host Defense Peptides," <u>Biopolymers</u> 37:105-122 (1995). **	
		Mancheño, J.M., et al., "A peptide of nine amino acid residues from alpha-sarcin cytotoxin is a membrane-perturbing structure," <u>J. Peptide Res.</u> 51:142-148 (1998). **	
		Pestonjamas et al., "Processing site and gene structure for the murine antimicrobial peptide CRAMP," <u>Peptides</u> 22:1643-1650 (2001). **	
		Roberts, and Vellaccio, <u>The Peptides: Analysis, Synthesis, Biology</u> vol. 5. Ed. Gross and Meinhofer. New York: Academic Press, 1983, 341. **	
		Silva et al., "Potential Tuberculostatic Agents: Micelle-Forming Copolymer Poly (ethylene glycol)-Poly (aspartic acid) Prodrug with Isoniazid," <u>Arch. Pharm. Pharm. Med. Chem.</u> 334:189-193 (2001). **	
		Stewart and Young, <u>Solid Phase Peptide Synthesis</u> 2nd ed. Rockford, Ill: Pierce Chemical Co., 1984. **	
		<u>The Merck Manual</u> . 16th Edn. Ed. Berkow, R. Rahway, N.J.: Merck Publishing, 1992. **	
		Yeaman and Bayer, "Antimicrobial peptides from platelets," <u>Drug Resistance Updates</u> 2:116-126 (1999). **	
		Yeaman et al., "Partial Characterization and Staphylocidal Activity of Thrombin-Induced Platelet Microbicidal Protein," <u>Infection and Immunity</u> 60:1202-1209 (1992). **	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will be provided under separate cover.

		Yeaman et al., "Resistance to Platelet Microbicidal Protein Results in Increased Severity of Experimental Candida albicans Endocarditis," <u>Infection and Immunity</u> 64:1379-1384 (1996). **	
		Yeaman, et al., <u>38th Interscience Conference on Antimicrobial Agents</u> San Diego, CA Abstract No. F-170 (1999). **	
		Yeaman, M., "The Role of Platelets in Antimicrobial Host Defense," <u>Clinical Infectious Diseases</u> 25:951-968 (1997). **	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will be provided under separate cover.